Behavior of SD-OCT-detected hyperreflective foci in the retina of anti-VEGF-treated patients with diabetic macular edema

Investigative Ophthalmology and Visual Science

Volumn 53, Issue 9, 2012, Pages 5814-5818

  Framme, Carsten ^a   Schweizer, Paul ^a   Imesch, Manfred ^a   Wolf, Sebastian ^a   Wolf Schnurrbusch, Ute ^a  

^a University Eye Clinic Bern   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; VASCULOTROPIN INHIBITOR; ANGIOGENESIS INHIBITOR; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; AUTOFLUORESCENCE; CENTRAL RETINAL THICKNESS; CLINICAL STUDY; DIABETIC MACULAR EDEMA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCANNING LASER OPHTHALMOSCOPY; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; VISUAL ACUITY; DIABETIC RETINOPATHY; DRUG ANTAGONISM; EXUDATE; INTRAVITREAL DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; OPTICAL COHERENCE TOMOGRAPHY; PATHOLOGY; PHYSIOLOGY; RETINA; RETINA MACULA EDEMA;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; DIABETIC RETINOPATHY; EXUDATES AND TRANSUDATES; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; RETINA; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84871696690     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.12-9950     Document Type: Article

References (17)

1. Framme C, Wolf S, Wolf-Schnurrbusch U. Small dense particles within the neurosensory retinal layers observable by spectral domain optical coherence tomography in age-related macular degeneration. Invest Ophthalmol Vis Sci. 2010;51:5965-5969.
2. Wolf S, Wolf-Schnurrbusch U. Spectral-domain optical coherence tomography use in macular diseases: a review. Ophthalmologica. 2010;224:333-340.
3. Bolz M, Schmidt-Erfurth U, Deak G, Mylonas G, Kriechbaum K, Scholda C; Diabetic Retinopathy Research Group Vienna. Optical coherence tomographic hyperreflective foci: a morphologic sign of extravasation in diabetic macular edema. Ophthalmology. 2009;116:914-920.
4. Ota M, Nishijima K, Sakamoto A, et al. Optical coherence tomographic evaluation of foveal hard exudates in patients with diabetic maculopathy accompanying macular detachment. Ophthalmology. 2010;117:1996-2002.
5. Uji A, Murakami T, Nishijima K, et al. Association between hyperreflective foci in the outer retina, status of photoreceptor layer, and visual acuity in diabetic macular edema. Am J Ophthalmol. 2012;153:710-717.
6. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419-1431.
7. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432-1444.
8. Regillo CD, Brown DM, Abraham P, et al. Randomized, doublemasked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol. 2008;145:239-248.
9. Massin P, Bandello F, Garweg JG, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study). Diabetes Care. 2010;33:2399-2405.
10. Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118:615-625.
11. Framme C, Panagakis G, Walter A, Gamulescu MA, Herrmann WA, Helbig H. Interobserver variability for re-treatment decision after ranibizumab upload in neovascular age-related macular degeneration. Acta Ophthalmol Scand. 2012;90:49-55.
12. Rothenbuehler SP, Waeber D, Brinkmann CK, Wolf S, Wolf-Schnurrbusch UEK. Effects of ranibizumab in patients with subfoveal choroidal neovascularization attributable to agerelated macular degeneration. Am J Ophthalmol. 2009;147: 831-837.
13. Kiss CG, Geitzenauer W, Simader C, Gregori G, Schmidt-Erfurth U. Evaluation of ranibizumab-induced changes of highresolution optical coherence tomographic retinal morphology and their impact on visual function. Invest Ophthalmol Vis Sci. 2009;50:2376-2383.
14. Pauleikhoff D, Kirchhof B. Retreatment criteria in anti-VEGF therapy of exudative AMD: critical analysis of present regimes and new morphological definition of "lesion activity" Graefes Arch Clin Exp Ophthalmol. 2011;249:631-632.
15. Stellungnahme der Deutschen Ophthalmologischen Gesellschaft, der Retinologischen Gesellschaft und des Berufsverbandes der Augenärzte Deutschlands zur Therapie der diabetischen Makulopathie. German Ophthalmologic Societey, the Retinologic Society, and the Professional Association of Ophthalmologists Germany; 2011. Available at: http://cms. augeninfo.de/fileadmin/stellungnahmen/17_01_2011_diabet_ makulopathie.pdf. Accessed March 15, 2012.
16. Diabetic Retinopathy Clinical Research Network. Vitrectomy outcomes in eyes with diabetic macular edema and vitreomacular traction. Ophthalmology. 2010;117:1087-1093.
17. Nowak JZ. Age-related macular degeneration (AMD): pathogenesis and therapy. Pharmacol Rep. 2006;58:353-363.